Apotex Corp.

Based in FL

🤖

AI Overview

With $9.0M in lobbying spend across 34 quarterly filings, Apotex Corp is one of the biggest lobbying spenders in Washington. Their lobbying covers 8 issue areas. Active from 2018 to 2025.

$9.0M

Total Spend

Years Active

Firms Hired

Lobbyists Deployed

Issues Lobbied

Spending Trend

View as table

Year	Lobbying Spend
2018	$1.5M
2019	$1.0M
2020	$870K
2021	$900K
2022	$900K
2023	$1.4M
2024	$680K
2025	$1.7M

Issues Lobbied

Lobbying Firms

Apotex Corp.

Lobbyists

Steven Giuli

Government Agencies Targeted

These are the government entities that Apotex Corp. disclosed contacting in their lobbying filings.

HOUSE OF REPRESENTATIVESSENATECommerce, Dept of (DOC)Executive Office of the President (EOP)Health & Human Services, Dept of (HHS)Natl Economic Council (NEC)Office of Management & Budget (OMB)Bureau of Industry and Security (BIS)Natl Security Council (NSC)U.S. Trade Representative (USTR)

View all agency pressure data →

What They Lobby About

These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Copyright/Patent, Budget/Appropriations, Pharmacy, Trade, Medicare/Medicaid and 3 more

Federal policy relating to inter partes review challenges of pharmaceutical and biotechnology patents.

HR 1892, the Bipartisan Budget Act of 2018, related to the inclusion of S.974/HR 2212, the Creating and Restoring Equal Access to Equivalent Samples Act; and

HR 1625, the Consolidated Appropriations

Federal policy related to Section 603, Applying the Medicaid additional rebate requirement to generics, of Public Law No 114-67, the Bipartisan Budget Act of 2015; and

S. 2476, the Expanding Access t

Federal policy related to the inclusion of provisions that enhance and facilitate generic drug and biosimilar competition in a revised North American Free Trade Agreement